Dyne Therapeutics, Inc.
DYNHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Dyne Therapeutics, Inc. (DYN) is listed under Biotechnology. With a market capitalization of $3.92B, it sits in mid-cap territory. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Market Cap
$3.92B
Beta
1.06
P/E (TTM)
—
P/E (Fwd)
-8.08
EPS (TTM)
$-3.29
EPS (Fwd)
$-2.94
ROE
-58.9%
ROA
-32.7%
Cash
$972.2M
Total Debt
$168.7M
Free CF
-$292.3M
52W Change
163.2%
Annual Financials
Cash vs Debt
With $972.2M in cash and $168.7M in debt, DYN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$292.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -58.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Dyne Therapeutics, Inc. and its sector.